Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™
Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements
Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia
Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out
Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels
Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia
Xenetic Biosciences Completes $3,000,000 Bridge Note Financing
Xenetic Biosciences Announces Board Change
Xenetic Biosciences to Hold Business Update Conference Call January 20th
